BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Brian (CFO), Cristin (Chief Commercial Officer) Key Highlights of 2025 - **Revenue Growth**: Total revenue grew by 13% in 2025, with Voxzogo revenue increasing by 26% and enzyme therapies by 9% [2][3] - **Profitability Improvement**: Earnings per share growth outpaced revenue growth, achieving over 2 times leverage on the bottom line after adjusting for special items [3] - **Amicus Acquisition**: Announcement of the acquisition of Amicus, expected to close in Q2 2026, which will add two high-growth rare disease assets to BioMarin's portfolio [3][4] 2026 Outlook - **Revenue Guidance**: Expected revenue growth in both enzyme therapies and skeletal conditions at 7%-8%, with a total revenue headwind of about 3% due to decreasing royalty and other revenues [4] - **Voxzogo Revenue Guidance**: Projected revenue for Voxzogo in 2026 is between $975 million and $1.025 billion, influenced by international market access negotiations and competitive impacts [14][15] - **Pipeline Advancements**: Anticipated phase 3 readouts for hypochondroplasia and BMN 401, with potential for significant market impact [5][47] Competitive Landscape - **Voxzogo Competition**: Voxzogo faces competition, but only 25% of its revenues are from the U.S., which is subject to competition, representing about 7% of total revenue [8][15] - **Market Positioning**: BioMarin is confident in Voxzogo's established position in the achondroplasia community, emphasizing the complexity of switching treatments for patients [7][8] Clinical Pipeline - **Hypochondroplasia**: Estimated total addressable patient population of 14,000, with a focus on increasing disease awareness and shortening diagnosis times [24][25] - **BMN 351**: A second-generation exon skipping therapy for Duchenne muscular dystrophy, showing promising early data with a target of 10% dystrophin expression [6] - **ENPP1 Deficiency**: Anticipated phase 3 data readout for BMN 401, with an estimated addressable patient population of 2,000-2,500 globally [47][48] Amicus Acquisition Impact - **Revenue Contribution**: Amicus products generated over $600 million in 2025, expected to enhance BioMarin's revenue portfolio significantly [18] - **Operational Synergies**: Anticipated operational expense synergies from integrating Amicus, with a focus on leveraging existing global capabilities [30][32] Financial Strategy - **Deleveraging Plan**: Target to reduce debt to less than 2.5 times within two years post-acquisition, with a focus on maintaining operational profitability [56][57] - **Future Business Development**: Continued interest in pipeline clinical stage transactions to enhance long-term revenue growth [58] Additional Insights - **Palynziq Expansion**: Recent label expansion for Palynziq to include adolescents, with an estimated 1,500 eligible patients in the U.S. [39][41] - **Seasonality in Revenue**: Historical trends indicate a ramp-up in revenue towards Q4, with a typical step down in Q1 due to international order timing [49][50] This summary encapsulates the key points discussed during the BioMarin Pharmaceutical FY Conference, highlighting the company's growth trajectory, competitive positioning, and strategic initiatives for the upcoming year.

Overview of PKU and Sephience - PKU (Phenylketonuria) is a rare genetic disorder where individuals cannot metabolize the amino acid phenylalanine, leading to its accumulation in the body, which severely impacts brain development and neurological function [1] - Newborn screening for PKU is critical, allowing early diagnosis and the initiation of a highly restrictive diet to prevent protein intake, which is essential for avoiding severe health consequences [1] - There are approximately 17,000 individuals in the United States diagnosed with PKU, with an estimated 58,000 affected globally in markets targeted for Sephience's therapy [1]

Summary of PTC Therapeutics FY Conference Call Company Overview - **Company**: PTC Therapeutics (NasdaqGS:PTCT) - **Event**: FY Conference Call on March 11, 2026 - **Speakers**: CEO Matt Klein, CFO Pierre Gravier Industry and Product Focus - **Disease**: Phenylketonuria (PKU) - A rare genetic disorder where individuals cannot break down the amino acid phenylalanine, leading to severe neurological consequences if untreated - Approximately **17,000 individuals** in the U.S. and **58,000 globally** are affected by PKU - **Product**: Sephience - A new therapy for PKU patients, aimed at providing a safe and effective treatment option Core Insights and Arguments - **Market Opportunity**: - Significant unmet medical need exists for PKU therapies, as prior treatments (Kuvan and Palynziq) did not adequately serve the majority of patients [2][3] - Sephience is positioned to address this need with a favorable safety and tolerability profile, allowing patients to have more dietary freedom [10][12] - **Patient Demand**: - There is a strong desire among PKU patients for effective therapies that can improve their quality of life [10][12] - Early launch metrics show over **1,100 starts** and **$110 million in revenue** within the first five and a half months, primarily from the U.S. market [14] - **Launch Strategy**: - The company has mapped out **104 centers of excellence** to understand decision-making dynamics, which include not just physicians but also nurse practitioners and dieticians [15] - Initial uptake has been broad, with patients across all age groups and severity levels being prescribed Sephience [18] - **Patient Segmentation**: - Majority of patients starting on Sephience are those who have previously tried and failed other therapies, with a notable number of therapy-naive patients also beginning treatment [19] - The company is focusing on getting patients who are currently untreated onto Sephience before switching those already on other therapies [22] - **Adherence and Discontinuation Rates**: - Early data indicates low discontinuation rates, with most patients responding positively to the therapy [34][35] - The expectation is that adherence will remain high due to the perceived benefits of the therapy [34] Financial Guidance - **Revenue Projections**: - Guidance for Sephience revenues is set at **$700 million to $800 million** for the year, with a global opportunity exceeding **$2 billion** [36][38] Other Important Insights - **Huntington's Disease Program**: - The votoplam program is progressing, with plans for a phase 3 trial and potential for accelerated approval based on interim analysis [41][42] - **Pipeline Development**: - The company is advancing several early-stage programs, including a phase 1 study for a NLRP3 inhibitor and other promising therapies targeting various conditions [49][50] Conclusion - PTC Therapeutics is positioned to make a significant impact in the PKU market with Sephience, addressing a critical unmet need and demonstrating strong early launch metrics. The company is also advancing its pipeline in other therapeutic areas, indicating a robust growth strategy moving forward.

Core Insights - The company achieved significant revenue growth in 2025, driven by the launch of Sephience, a drug for PKU, generating over $111 million in revenue within the first 5.5 months [1] - The company ended 2025 with approximately $1.95 billion in cash, positioning itself well for future commercial and R&D initiatives [2] - Continued strong momentum is expected in the U.S. market, with revenue growth anticipated to be driven by Sephience throughout the year [3]

Summary of PTC Therapeutics Conference Call Company Overview - **Company**: PTC Therapeutics (NasdaqGS:PTCT) - **Key Product**: Sephience, a drug for phenylketonuria (PKU) Recent Accomplishments - **2025 Performance**: Strong revenue of over $111 million in the first five and a half months, exceeding guidance [3][4] - **Cash Position**: Ended 2025 with approximately $1.95 billion in cash, supporting commercial and R&D activities [4] - **Revenue Growth**: Anticipated continued growth driven by Sephience, with expectations of commercial patients in 20-30 countries by year-end [4] Sephience Launch Insights - **Patient Demographics**: Broad uptake across various age groups, including therapy-naive patients and those switching from other therapies [6][10] - **Center Participation**: Over 80% of centers of excellence have prescribed Sephience, indicating strong initial engagement [10] - **Durability of Demand**: Early performance suggests sustained momentum, with a significant number of patients remaining on the drug [11][12] Clinical Data and Patient Outcomes - **Response Rates**: 70%-75% response rate in clinical trials, with high adherence rates observed in real-world settings [18][20] - **Quality of Life Improvements**: Reports of improved cognitive function and dietary flexibility among patients [16][30][34] - **Phe Level Control**: 84% of patients achieved target phenylalanine levels, allowing increased protein intake [32][34] Payer Engagement and Market Strategy - **Payer Feedback**: Positive responses from payers, with no step edits required for coverage, indicating strong value proposition [28][29] - **Market Opportunity**: Sephience is projected to be a $2 billion-plus global opportunity at peak [14] Future Development Plans - **Lifecycle Management**: Plans to develop a tablet formulation to address patient concerns about taste and texture [20][22] - **Pipeline Programs**: Focus on vatiquinone for Friedreich's ataxia and votoplam for Huntington's disease, with potential for significant revenue contributions [41][42] R&D and Innovation - **Splicing Platform**: Advances in RNA splicing technology, with multiple preclinical programs in development [58][59] - **Partnership Strategy**: Open to partnerships for non-core therapeutic areas while focusing on internal development for rare diseases [61] Conclusion - PTC Therapeutics is well-positioned for growth with a strong cash position, promising product performance, and a robust pipeline. The company is actively engaging with payers and exploring lifecycle management strategies to enhance the value of Sephience while continuing to innovate in its R&D efforts.

Summary of PTC Therapeutics FY Conference Call (March 02, 2026) Company Overview - **Company**: PTC Therapeutics (NasdaqGS:PTCT) - **Industry**: Biotechnology, focusing on rare diseases and RNA-targeted therapies Key Highlights from 2025 and Early 2026 - **Sephience Launch**: - First approvals and global launch for Sephience for patients with Phenylketonuria (PKU) achieved in the U.S., Europe, and Japan within six months, generating over **$111 million** in revenue in the first 5.5 months [2][5] - Sephience is viewed as a **multi-billion dollar** opportunity, with expectations of reaching **$2 billion** in global sales [5][31] - **Financial Position**: - Closed 2025 with **$1.95 billion** in cash, providing flexibility and protection against uncertainties [3] - Operating expenses (OpEx) came in below guidance, with potential to reach cash flow break-even in 2026 [6][36] Sephience Market Penetration - **Patient Demographics**: - Early uptake includes a broad range of patient subtypes, including therapy-naive patients and those who have failed previous treatments [8][11] - The total addressable market in the U.S. is approximately **17,000** patients with PKU [9] - **Centers of Excellence**: - Over **80%** of centers of excellence have initiated at least one patient on Sephience, indicating strong early penetration [10] - **Patient Retention**: - Early refill rates are high, with low discontinuation rates in the low single digits, suggesting strong adherence to the therapy [16][17] Competitive Landscape - **Market Dynamics**: - There are misconceptions about the need for patients to fail on generic Kuvan before accessing Sephience; however, no step edits have been observed in payer policies [21] - The company is not currently worried about competition, as it believes Sephience will establish itself as the standard of care [39] International Expansion - **Global Strategy**: - Launch in Germany has shown early interest, with pricing and reimbursement processes underway [23] - Japan is prioritized as a high-value market, with expectations for launch in early Q2 2026 [24] - The company is also exploring opportunities in Brazil and other regions, including the Middle East and North Africa [27] Financial Guidance and Future Outlook - **Revenue Guidance**: - The majority of 2026 revenue is expected to come from Sephience, with a potential decline in revenue from more mature products due to increased competition [32][34] - **Long-term Vision**: - The company aims for cash flow break-even in 2026 and has IP protection extending to **2039**, indicating a long-term growth strategy [31][36] R&D Pipeline and Future Developments - **Ongoing Programs**: - Continued advancement in R&D, particularly in RNA splicing and inflammation platforms [5][62] - Excitement around the MSH3 program and NLRP3 program, with plans to move into clinical trials soon [62] Conclusion - PTC Therapeutics is positioned strongly in the biotechnology sector with a successful launch of Sephience, a robust financial position, and a promising pipeline of therapies. The company is focused on expanding its market presence while maintaining operational efficiency and preparing for future growth opportunities.

Core Insights - PTC Therapeutics reported significant growth in revenue driven by the launch of Sephience for phenylketonuria (PKU), achieving $92 million in the fourth quarter and $111 million since its launch in 2025 [1][4][7] - The company exceeded its revenue guidance for 2025, reporting total net product and royalty revenue of $831 million, up from the previous guidance of $750 million to $800 million [2][6] Financial Performance - For Q4 2025, PTC's total net product and royalty revenue was $263 million, contributing to a full-year total of $831 million [2][4] - The company ended 2025 with $1.95 billion in cash, following the monetization of Evrysdi royalties for $240 million upfront [6][22][23] - PTC guided for 2026 product revenue between $700 million and $800 million, indicating a growth of 19% to 36% compared to 2025 [24] Product Development and Approvals - Sephience received approvals in the U.S., E.U., and Japan, with early commercial momentum noted through broad uptake across various patient demographics [3][7][8] - The company plans to expand Sephience's commercial footprint internationally, targeting 20 to 30 countries by the end of 2026 [11][13] Market Dynamics - Payers have shown favorable early reimbursement for Sephience, with minimal barriers to access and long refill periods [9][10] - The company is addressing the needs of "lost to follow-up" adults, leveraging social media and community networks to re-engage patients [10] Pipeline Updates - PTC is advancing its pipeline with Votoplam for Huntington's disease, with a phase III trial expected to start in H1 2026 [5][18] - For Vatiquinone, an additional study is required for NDA resubmission, with plans to align on the protocol with the FDA [19] Other Revenue Streams - The Duchenne muscular dystrophy (DMD) franchise contributed $66 million in Q4, with Evrysdi royalties generating $79 million [14][15] - The company continues to face challenges in the DMD market due to increased generic competition [15]

Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [5][17] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [6] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [5][12] - The DMD franchise revenue for Q4 2025 was $66 million, with Translarna contributing $39 million and Emflaza $27 million [17] - Evrysdi royalty revenue for full-year 2025 was $244 million [18] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide by the end of 2025 [13] - In the U.S., 80% of PKU Centers of Excellence have written prescriptions for Sephience [13] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, with Japan's launch anticipated soon [8][15] Company Strategy and Development Direction - The main focus for 2026 will be to continue the momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and geographic expansion [7][8] - The company aims to reach cash flow break-even in 2026, a significant milestone [7][20] - The R&D pipeline includes advancing programs from RNA splicing and ferroptosis inflammation platforms, with several early-stage programs expected to progress [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Sephience's potential, citing a multi-billion dollar global revenue opportunity due to its differentiated profile and unmet need in the PKU market [8][15] - The management highlighted the importance of social media in driving awareness and engagement among patients, particularly those previously lost to follow-up [30][31] - The company remains optimistic about the future, with a robust commercial engine and innovative R&D programs [10] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025, which will not generate cash proceeds for PTC but maintains the right to receive a $150 million milestone from Roche [19][20] - The company is preparing for pricing and reimbursement negotiations in key markets, including Japan and Brazil, with expectations for meaningful revenue contributions from these regions [15][70] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance of $700 million-$800 million is primarily from Sephience, with contributions expected from mature products as well [22][23] Question: How are lost to follow-up patients becoming aware of Sephience? - Engagement through social media has played a significant role in raising awareness among patients who were previously lost to follow-up [30][31] Question: Can you provide details on the additional study requested by the FDA for vatiquinone? - The FDA suggested an open-label or single-arm study with a natural history comparator group, and the company plans to meet with the FDA to finalize the protocol [39][40] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with high prescription renewal rates, which is encouraging for future growth [46][47] Question: How will pricing and reimbursement dynamics evolve in Europe? - The company is in the process of negotiating pricing and reimbursement in Germany, with expectations for a favorable outcome based on strong clinical data [52][53]

Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [5][17] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [6] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [5][12] - The DMD franchise revenue for Q4 2025 was $66 million, with Translarna contributing $39 million and Emflaza $27 million [17] - Evrysdi royalty revenue for full-year 2025 was $244 million [18] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide as of December 31, 2025 [13] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, including Japan and Brazil [8][15] Company Strategy and Development Direction - The main focus for 2026 is to continue the strong momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and geographic expansion [7][8] - The company plans to advance several programs from its innovative R&D platforms, including RNA splicing and ferroptosis inflammation [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential multi-billion dollar global revenue opportunity for Sephience, citing its differentiated profile and broad uptake [8][12] - The company anticipates reaching cash flow break-even in 2026, a significant milestone [7][20] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025 [19] - The FDA has requested an additional study for Vatiquinone, which the company plans to pursue [39] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance for 2026 is $700 million-$800 million, with the majority expected from Sephience, and contributions from mature products [22][23] Question: How are lost to follow-up patients becoming aware of Sephience? - Many adults previously lost to follow-up are now seeking therapy due to social media awareness and positive patient experiences shared online [30][31] Question: What are the dynamics for Vatiquinone's additional study? - The FDA suggested an open-label or single-arm study with a natural history comparator group, which the company plans to discuss further [39][40] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with high prescription renewal rates, indicating strong early adoption [46][47] Question: How will Sephience's growth in Europe be affected after the free pricing period? - The company anticipates maintaining a strong price based on the clinical data package and ongoing negotiations [51][53]

Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [4][15] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [5] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [18] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [4][10] - DMD franchise revenue for Q4 2025 was $66 million, with Translarna and Emflaza contributing $39 million and $27 million, respectively [15] - Evrysdi royalty revenue for full-year 2025 was $244 million [15] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide by the end of 2025 [11] - The U.S. accounted for the majority of Sephience revenue, with $81 million generated in Q4 2025 [10] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, including Japan and Brazil [7][13] Company Strategy and Development Direction - The main focus for 2026 is to continue the strong momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and expansion into additional geographies [6][7] - The company plans to advance several programs from its innovative R&D platforms, including RNA splicing and ferroptosis inflammation [9] - The company aims to reach cash flow break-even in 2026, a significant milestone [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Sephience's potential, citing a multi-billion dollar global revenue opportunity due to its differentiated profile and large unmet need [7] - The management highlighted the importance of social media in raising awareness and driving patient engagement for Sephience [29] - The company anticipates continued strong performance from its mature products despite headwinds in the DMD franchise [14] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025 [16] - The FDA has requested an additional study for vatiquinone, which the company plans to pursue [34][36] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance for 2026 is $700 million-$800 million, with the majority expected from Sephience, and adjustments may be made as visibility improves [20][21] Question: How are lost to follow-up patients becoming aware of Sephience? - Social media has played a significant role in raising awareness among patients who were previously lost to follow-up, leading to increased engagement with healthcare providers [29] Question: Can you provide details on the additional study requested by the FDA for vatiquinone? - The FDA suggested an open-label or single-arm study with a natural history comparator group, and the company plans to meet with the FDA to finalize the protocol [36][39] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with most dropouts being patient decisions rather than clinical reasons [44] Question: How is the pricing and reimbursement process for Sephience in Germany? - The company has submitted its HTA dossier and is in discussions for pricing and reimbursement, expecting to maintain a high list price based on strong clinical data [51]